Yasuto Naoi

2.5k total citations
88 papers, 1.5k citations indexed

About

Yasuto Naoi is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Yasuto Naoi has authored 88 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Cancer Research, 43 papers in Oncology and 37 papers in Molecular Biology. Recurrent topics in Yasuto Naoi's work include Breast Cancer Treatment Studies (37 papers), Cancer Genomics and Diagnostics (24 papers) and HER2/EGFR in Cancer Research (20 papers). Yasuto Naoi is often cited by papers focused on Breast Cancer Treatment Studies (37 papers), Cancer Genomics and Diagnostics (24 papers) and HER2/EGFR in Cancer Research (20 papers). Yasuto Naoi collaborates with scholars based in Japan, United States and Russia. Yasuto Naoi's co-authors include Shinzaburo Noguchi, Kenzo Shimazu, Seung Jin Kim, Naofumi Kagara, Masafumi Shimoda, Atsushi Shimomura, Tomonori Tanei, Naomi Maruyama, Tomohiro Miyake and Yasuhiro Tamaki and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Yasuto Naoi

81 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yasuto Naoi Japan 23 850 662 661 290 276 88 1.5k
Yi-Zhou Jiang China 23 827 1.0× 648 1.0× 681 1.0× 282 1.0× 172 0.6× 41 1.5k
S. Michael Rothenberg United States 22 501 0.6× 737 1.1× 882 1.3× 403 1.4× 201 0.7× 45 1.8k
Paul J. van Diest Netherlands 22 454 0.5× 549 0.8× 833 1.3× 184 0.6× 286 1.0× 40 1.6k
Nadège Gruel France 19 477 0.6× 471 0.7× 647 1.0× 187 0.6× 196 0.7× 37 1.3k
David Huntsman Canada 17 377 0.4× 681 1.0× 567 0.9× 295 1.0× 177 0.6× 28 1.4k
Hans Halfwerk Netherlands 15 787 0.9× 525 0.8× 553 0.8× 158 0.5× 232 0.8× 19 1.2k
María Ángeles López‐García Spain 19 946 1.1× 735 1.1× 1.1k 1.6× 287 1.0× 280 1.0× 27 1.9k
Yi‐Rong Liu China 22 862 1.0× 523 0.8× 865 1.3× 343 1.2× 119 0.4× 44 1.6k
Nikita Makretsov Canada 14 380 0.4× 593 0.9× 682 1.0× 164 0.6× 195 0.7× 19 1.4k
Kay Friedrichs Germany 16 479 0.6× 674 1.0× 521 0.8× 163 0.6× 154 0.6× 34 1.4k

Countries citing papers authored by Yasuto Naoi

Since Specialization
Citations

This map shows the geographic impact of Yasuto Naoi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuto Naoi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuto Naoi more than expected).

Fields of papers citing papers by Yasuto Naoi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuto Naoi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuto Naoi. The network helps show where Yasuto Naoi may publish in the future.

Co-authorship network of co-authors of Yasuto Naoi

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuto Naoi. A scholar is included among the top collaborators of Yasuto Naoi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuto Naoi. Yasuto Naoi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Seno, Shigeto, Yasuto Naoi, Keiichiro Honma, et al.. (2025). IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses. Breast Cancer. 32(3). 566–581.
2.
Konishi, Eiichi, Isao Yokota, Shogen Boku, et al.. (2024). Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(8). 167458–167458. 2 indexed citations
3.
4.
5.
Ooe, Asako, et al.. (2023). Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib. Anticancer Research. 43(6). 2783–2789. 2 indexed citations
6.
7.
Sato, Yasufumi, Masafumi Shimoda, Tomohiro Miyake, et al.. (2021). Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody. Cancer Medicine. 10(4). 1418–1430. 9 indexed citations
8.
Naoi, Yasuto, Masafumi Shimoda, Tomonori Tanei, et al.. (2021). Impact of tumor cellularity on the HER2 amplification assay by OncoScan™ in breast cancer. Breast Cancer. 28(4). 977–982.
9.
Kim, Seung Jin, Yasuto Naoi, Keiichiro Honma, et al.. (2020). Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer. Translational Oncology. 14(2). 100986–100986. 12 indexed citations
10.
Miyake, Tomohiro, Kenzo Shimazu, Tomonori Tanei, et al.. (2019). Hookwire-guided Sentinel Lymph Node Biopsy Using Contrast-enhanced Ultrasonography Followed by a One-step Nucleic Acid Amplification (OSNA) Assay for Breast Cancer. Anticancer Research. 39(11). 6183–6192. 7 indexed citations
11.
Naoi, Yasuto, Kenzo Shimazu, Masafumi Shimoda, et al.. (2019). Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC. Breast Cancer Research and Treatment. 174(3). 627–637. 15 indexed citations
12.
Shimazu, Kenzo, Tomohiro Miyake, Jun Okuno, et al.. (2019). One-step Nucleic Acid Amplification Can Identify Sentinel Node-negative Breast Cancer Patients With Excellent Prognosis. Anticancer Research. 39(3). 1447–1454. 12 indexed citations
13.
Shimoda, Masafumi, Yasuto Naoi, Naofumi Kagara, et al.. (2019). Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer. Breast Cancer Research. 21(1). 88–88. 42 indexed citations
14.
15.
Shimazu, Kenzo, Tomohiro Miyake, Tomonori Tanei, et al.. (2019). Real-Time Visualization of Lymphatic Flow to Sentinel Lymph Nodes by Contrast-Enhanced Ultrasonography with Sonazoid in Patients with Breast Cancer. Ultrasound in Medicine & Biology. 45(10). 2634–2640. 20 indexed citations
16.
Kagara, Naofumi, Tomohiro Miyake, Tomonori Tanei, et al.. (2017). Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing. Breast Cancer Research and Treatment. 163(2). 231–240. 28 indexed citations
17.
Shimoda, Masafumi, Naofumi Kagara, Yasuto Naoi, et al.. (2016). Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. Breast Cancer Research and Treatment. 157(1). 55–63. 40 indexed citations
18.
Naoi, Yasuto & Shinzaburo Noguchi. (2015). Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer. 23(1). 12–18. 30 indexed citations
19.
Naoi, Yasuto, Kenzo Shimazu, Naomi Maruyama, et al.. (2014). Development of a prediction model for lymph node metastasis in luminal A subtype breast cancer: The possibility to omit sentinel lymph node biopsy. Cancer Letters. 353(1). 52–58. 9 indexed citations
20.
Miyake, Tomohiro, Takahiro Nakayama, Yasuto Naoi, et al.. (2012). GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER‐negative breast cancer. Cancer Science. 103(5). 913–920. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yi-Zhou Jiang Breakdown of academic impact, for papers by S. Michael Rothenberg Breakdown of academic impact, for papers by Paul J. van Diest Breakdown of academic impact, for papers by Nadège Gruel Breakdown of academic impact, for papers by David Huntsman Breakdown of academic impact, for papers by Hans Halfwerk Breakdown of academic impact, for papers by María Ángeles López‐García Breakdown of academic impact, for papers by Yi‐Rong Liu Breakdown of academic impact, for papers by Nikita Makretsov Breakdown of academic impact, for papers by Kay Friedrichs
Rankless by CCL
2026